Craft

OptiNose

Stock Price

$1

2024-07-22

Market Capitalization

$117.6 M

2024-07-22

Revenue

$71 M

FY, 2023

OptiNose Summary

Company Summary

Overview
OptiNose develops nasal drug delivery technologies and combination drug-device therapies. It offers liquid delivery and powder delivery devices based on Bi-Directional Exhalation Delivery Systems (EDS). The company focuses on the treatment of chronic rhinosinusitis, nasal polyps, and chronic sinusitis.
Type
Public
Status
Active
Founded
2000
HQ
Morrisville, PA, US | view all locations
Website
https://www.optinose.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Ramy A. Mahmoud

    Ramy A. Mahmoud, Chief Executive Officer and Director

  • Paul Spence

    Paul Spence, Chief Commercial Officer

  • Mike Marino

    Mike Marino, Chief Legal Officer

  • Ramona Lloyd

    Ramona Lloyd, Senior Vice President, Regulatory & Quality

Operating MetricsView all

Patents Pending (US)

35

Jun, 2017

Trademarks (US)

3

Jun, 2017

Patents (US)

43

Jun, 2017

LocationsView all

3 locations detected

  • Morrisville, PA HQ

    United States

    1020 Stony Hill Rd #300

  • Oslo, Oslo

    Norway

    Gaustadalléen 21

  • Swindon, England

    United Kingdom

    Berkeley House, Hunts Rise

OptiNose Financials

Summary Financials

Revenue (Q1, 2024)
$14.9M
Gross profit (Q1, 2024)
$13.6M
Net income (Q1, 2024)
($14.1M)
Cash (Q1, 2024)
$51.6M
EBIT (Q1, 2024)
($8.1M)
Enterprise value
$196.6M

Footer menu